In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 352-357

  Yong, Dongeun ^a   Yum, Jong Hwa ^a   Lee, Kyungwon ^a   Chong, Yunsop ^a   Choi, Sung Hak ^b   Rhee, Jae Keol ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

[N 3 [4 [2 (1 METHYL 5 TETRAZOLYL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL ACETAMIDE; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DA 7867; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULFAMETHOXAZOLE; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-INFECTIVE AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BACTEROIDES; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-NEGATIVE BACTERIA; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 0347361703     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.352-357.2004     Document Type: Article

References (20)

1. Anderegg, T. R., D. J. Biedenbach, and R. N. Jones. 2002. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob. Agents Chemother. 46:2662-2664.
2. Chong, Y., K. Lee, O. H. Kwon, and J. Henrichsen. 1995. Capsular types and antimicrobial resistance of Streptococcus pneumoniae isolated in Korea. Eur. J. Clin. Microbiol. Infect. Dis. 14:528-531.
3. Diekema, D. J., and R. N. Jones. 2001. Oxazolidinone antibiotics. Lancet 358:1975-1983.
4. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 2002. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J. Antimicrob. Chemother. 50:101-105.
5. Eliopoulos, G. M., C. B. Wennersten, and R. C. Moellering, Jr. 2002. In vitro activity of the new oxazolidinone AZD2563 against enterococci. Antimicrob. Agents Chemother. 46:3273-3275.
6. Fluit, A. C., F. J. Schmitz, J. Verhoef, and D. Milatovic. 2002. In vitro activity of AZD2563, a novel oxazolidinone, against European gram-positive cocci. J. Antimicrob. Chemother. 50:271-276.
7. Jacqueline, C., J. Caillon, V. Le Mabecque, A. F. Miegeville, P. Y. Donnio, D. Bugnon, and G. Potel. 2003. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J. Antimicrob. Chemother. 51:857-864.
8. Johnson, A. P., M. Warner, and D. M. Livermore. 2000. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J. Antimicrob. Chemother. 45:225-230.
9. Lee, K., C. H. Chang, N. Y. Lee, H. S. Kim, K. S. Hong, and H. C. Cho. 2000. Korean nationwide surveillance of antimicrobial resistance in 1998. Yonsei Med. J. 41:497-506.
10. Lee, K., J. W. Shin, and Y. Chong. 2000. Trends in serotypes and antimicrobial susceptibility of group B streptococci isolates in Korea. J. Infect. Chemother. 6:93-97.
11. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. 2):9-16.
12. Morikawa, Y., M. Kitazato, C. Katsukawa, and A. Tamaru. 2003. Prevalence of cefotaxime resistance in group B streptococcus isolate from Osaka, Japan. J. Infect. Chemother. 9:131-133.
13. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. Thirteenth informational supplement, M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Nord, C. E., and C. Edlund. 1990. Impact of antimicrobial agents on human intestinal microflora. J. Chemother. 2:218-237.
16. Phillips, O. A., V. O. Rotimi, W. Y. Jamal, M. Shahin, and T. L. Verghese. 2003. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria. J. Chemother. 15:113-117.
17. Shin, J. W., D. Yong, M. S. Kim, K. H. Chang, K. Lee, J. M. Kim, and Y. Chong. 2003. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J. Infect. Chemother. 9:62-67.
18. Sweeney, M. T., and G. E. Zurenko. 2003. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob. Agents Chemother. 47:1902-1906.
19. Yong, D., H. J. Cheong, Y. S. Kim, Y. J. Park, W. J. Kim, J. H. Woo, K. Lee, M. W. Kang, and Y. S. Choo. 2002. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. J. Korean Med. Sci. 17:737-742.
20. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilbyrn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.